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Activation of the innate response initiated by 
TLRs is an essential mechanism of defense 
against many pathogens; however, TLR can 
also respond to endogenous ligands, potentially 
leading to autoimmunity if not properly con-
trolled. This is particularly clear for the nucleic 
acid receptors TLR7 and 9, which appear to 
mediate the pathogenesis of several autoim-
mune diseases, most notably lupus. In lupus, 
TLR7 and TLR9 recognition of endogenous 
RNA and DNA, respectively, results in the pro-
duction of type I IFNs and the anti-DNA and 
ribonucleoprotein (RNP) autoantibodies char-
acteristic of the disease. In mice, an increased 
copy number of the TLR7 gene leads to a lupus-
like syndrome characterized by accumulation 
of RNP-specific autoantibodies (Pisitkun et al., 
2006; Subramanian et al., 2006; Deane et al., 
2007; Walsh et al., 2012). In lupus-prone MRL/
lpr mice, deletion of the TLR7 gene reduced 
the level of anti-RNP autoantibodies but not 
the level of anti-dsDNA antibodies, which 
depends on TLR9 expression (Christensen et al., 
2006; Nickerson et al., 2010). These results 
clearly suggest that the two major classes of 
autoantigens targeted in lupus, DNA- and RNA-
binding proteins are specifically controlled by 
TLR9 and TLR7, respectively. Furthermore, 
treatment of the lupus prone (NZBxNZW)F1 
mice with a TLR7 and 9 inhibitor leads to 
reduced symptoms and increased survival 
(Barrat et al., 2007). It is not known whether 
the second endosomal receptor for single-
stranded RNA (ssRNA), TLR8, could likewise 
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Studies on the role of the RNA receptor TLR8 in inflammation have been limited by its 
different function in human versus rodents. We have generated multiple lines of transgenic 
mice expressing different levels of human TLR8. The high copy number chimeras were 
unable to pass germline; developed severe inflammation targeting the pancreas, salivary 
glands, and joints; and the severity of the specific phenotypes closely correlated with the 
huTLR8 expression levels. Mice with relatively low expression levels survived and bred 
successfully but had increased susceptibility to collagen-induced arthritis, and the levels of 
huTLR8 correlated with proinflammatory cytokines in the joints of the animals. At the 
cellular level, huTLR8 signaling exerted a DC-intrinsic effect leading to up-regulation of 
co-stimulatory molecules and subsequent T cell activation. A pathogenic role for TLR8 in 
human diseases was suggested by its increased expression in patients with systemic arthritis 
and the correlation of TLR8 expression with the elevation of IL-1b levels and disease 
status. We found that the consequence of self-recognition via TLR8 results in a constella-
tion of diseases, strikingly distinct from those related to TLR7 signaling, and points to 
specific inflammatory diseases that may benefit from inhibition of TLR8 in humans.
© 2013 Guiducci et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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mRNA expression in these chimeras correlated negatively 
with survival (Fig. 1 B). Interestingly, spontaneous disease 
was observed even in mice with as few as 20% of the blood 
cells derived from the huTLR8 transgenic ES cells, dem-
onstrating a strong dominant biological effect (Fig. 1 C). Chi-
meras from a fourth ES clone, Clone 8, (TLR8TgCL8) had 
a lower level of transgene expression (Fig. 1 D), and bred nor-
mally, allowing establishment of a stable transgenic line on 
C57BL/6 background.
PBMCs isolated from all the transgenic lines responded to 
the RNA-based ligand of human TLR8 (ORN-8L; Lan et al., 
2007; Fig. 1 E), whereas PBMCs from nontransgenic mice 
were unresponsive to these ligands (Fig. 1 E). These data dem-
onstrated that huTLR8 is active when expressed in mice and 
that is not constitutively activated in the transgenic chimeras, 
as no spontaneous production of cytokines was detected in 
cultured PBMCs in the absence of TLR8 agonists (Fig. 1 E). 
Proteolysis by endolysosomal protease is required for sig-
naling of TLR7, TLR9, and TLR3 (Ewald et al., 2011; 
Maschalidi et al., 2012). Treatment with bafilomycin A1, an 
inhibitor of the vacuolar ATPase which blocks acid-dependent 
protease activity, prevents TLR8 activation both in human 
PBMCs and PBMCs from huTLR8 transgenic mice (Fig. 1, 
F and G). These data demonstrate that the dependence on 
receptor proteolysis is preserved when human TLR8 is 
expressed in mouse cells.
Histopathological evaluation of the chimeras revealed 
inflammation in the pancreas, kidneys, liver, salivary glands, 
and the joints. The disease patterns in mice generated from 
the three independent ES clones were essentially the same, 
suggesting that the phenotype is due to the transgene itself, 
not to an insertional mutation in the host genome (Fig. 2, 
A and B; and Fig. S2 A). The pancreas was the most severely af-
fected organ and the likely cause of death in these mice, with 
pancreatic acinar tissue substantially effaced by inflammatory 
cells, primarily macrophages, lymphocytes, and neutrophils. 
Residual islets could be identified within the inflammatory 
tissue, suggesting that the exocrine pancreas was the main tar-
get of the inflammatory reaction (Fig. 2 A, I and II; and Fig. S2, 
A and B). Kidney sections revealed two prominent types of 
lesions: pyelitis (Fig. 2 A, III and IV) and glomerulonephritis 
(Fig. 2 A, V and VI). Liver hepatic sections (Fig. 2 A, VII and 
VIII) revealed an inflammatory reaction mainly localized in 
the portal triads (Fig. S2 A). The inflammatory changes associ-
ated with the bile ducts are consistent with an autoimmune 
origin resembling autoimmune cholangiopathy in humans. 
Similarly affected were salivary glands that were severely com-
promised by an inflammatory infiltrate similar to that seen 
in the other organs (not depicted).
Lungs, brain, heart, and stomach tissues were not 
affected, suggesting selective inflammation of specific tis-
sues. Serum levels of several inflammatory cytokines were 
elevated in huTLR8Tg chimeras (Fig. 2 C) and correspond-
ing elevation of the mRNA of these cytokines were mea-
sured in pancreas of the affected animals (Fig. 2 D). Increased 
levels of antinuclear antibodies, dsDNA antibodies, and 
mediate autoimmunity and, if so, which diseases would result 
from its dysfunction.
In humans, TLR8, like TLR7, recognizes viral RNA, self-
RNA within snRNP autoantibodies complexes, and several 
classes of small molecule agonists (Gorden et al., 2005; 
Vollmer et al., 2005; Forsbach et al., 2008; Gantier et al., 2008; 
Ablasser et al., 2009; Liu et al., 2010). However, numerous 
differences exist among these two receptors. TLR8 is prefer-
entially activated by ssRNA rich in AU, whereas sequences 
rich in GU preferentially activate TLR7 (Forsbach et al., 
2008). Additionally, TLR8 senses ssRNA through its ability to 
form secondary structures, a characteristic not required for 
TLR7 activation (Sarvestani et al., 2012). Lastly, the pattern of 
expression of the two receptors differs among human blood 
cells. TLR7 is largely coexpressed with TLR9, primarily on 
B cells and PDCs (plasmacytoid DCs), whereas TLR8 is absent 
in these cells and abundantly expressed in monocytes, myeloid 
DCs (mDCs), and neutrophils (see Fig. 9 A; Hattermann et al., 
2007; Forsbach et al., 2008; Janke et al., 2009), suggesting that 
activation of human TLR8 by endogenous ligands might lead 
to a different spectrum of inflammatory disease than the one 
resulting from activation of TLR7 and TLR9.
Circumstantial evidence implicates a role of TLR8 in 
human diseases, including RA (Sacre et al., 2008), antiphos-
pholipid syndrome (APS; Döring et al., 2010), and IBD 
(Prinz et al., 2011). These reports rely mostly on gene poly-
morphism and correlative studies. The absence of small animal 
models has limited studies of the disease associations of TLR8 
signaling. Mouse TLR8 does not recognize ssRNA ligands, 
RNA viruses, or small molecules that are potent agonists for 
human TLR8 (Hemmi et al., 2002; Heil et al., 2004) a dif-
ference caused by the absence of 5 aa that are necessary for 
RNA recognition by human TLR8 (Liu et al., 2010). Thus, 
the role of self-recognition by TLR8 cannot be meaningfully 
studied in current mouse models of autoimmunity and a 
more relevant small animal model would represent a signifi-
cant advantage in the field. In this study, we have thus gener-
ated multiple human TLR8 transgenic lines of ES cells and 
generated chimeric mice from these ES lines to study human 
TLR8 function in vivo.
RESULTS
Mice with high expression of human TLR8  
develop multiorgan inflammatory syndrome
To develop a small animal model to study human TLR8 func-
tion, we generated transgenic mice expressing human 
TLR8 under the control of human TLR8 genomic regulatory 
regions. A BAC clone containing the complete human 
TLR7 and TLR8 genomic region was modified to delete the 
huTLR7 coding region, leaving only the huTLR8 gene 
capable of expression. Transfection of a C57BL/6 ES cell 
line with this construct produced many clones, four of which 
were selected to generate transgenic mice (Fig. S1). Chimeras 
produced from three of these clones (6, 12, and 23) devel-
oped a wasting disease, surviving from 23 and 140 d (Fig. 1 A), 
and failing to breed successfully. The level of huTLR8 
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showed a pattern of severe inflammation in pancreas, liver, 
and salivary glands comparable to that in chimeric huTLR8Tg 
mice, and pancreas failure was similarly considered the primary 
cause of death (Fig. 3 B). However, huTLR8Tg reconstituted 
mice, in contrast to transgenic chimeras, showed no evidence 
for glomerulonephritis or kidney pyelitis (Fig. 3 B), and 
circulating antibodies against self-nucleic acids were not 
detected (not depicted). This could be due to the more rapid 
response observed in the reconstituted mice, but this also sug-
gests that anti-nucleic acid autoantibodies contribute to the 
glomerulonephritis in huTLR8Tg chimeras but are not re-
quired for inflammation in the other affected organs.
Unlike chimeras, virtually all BM-derived cells were of 
transgenic origin, simplifying the analysis of the expression 
patterns of huTLR8 in the hematopoietic compartment. The 
distribution of huTLR8 among mouse blood cells was similar to 
its expression pattern in human leukocyte subsets, suggesting 
that the disease in mice was not due to a highly atypical pat-
tern of cellular expression (Fig. 3 C).
To better understand the pathogenic changes, we analyzed 
the cellular compartment in the chimeric mice. The absolute 
number of circulating leukocytes in the blood and in the 
spleens was significantly decreased in huTLR8Tg chimeras 
(Fig. 4 A). The observed leukopenia is the result of a decreased 
anti-RNPs (Fig. 2 E) were also measured at sacrifice in 
moribund chimeric mice.
DC-intrinsic huTLR8 activation and subsequent T cell 
activation promote the inflammatory syndrome
This characteristic pattern of spontaneous multiorgan in-
flammation could reflect either responses intrinsic to the 
inflammatory cells themselves or the consequences of trans-
gene expression in cells of the affected tissues, or both. To test 
these alternatives, bone marrow from each of the three inde-
pendent huTLR8-expressing chimeras was transferred to 
irradiated congenic B6SJL mice. All reconstituted mice spon-
taneously developed a disease pattern remarkably similar to 
that observed in the chimeras, demonstrating that the ex-
pression of huTLR8 in the hematopoietic compartment is 
sufficient to generate the full spectrum of inflammatory dis-
ease (Fig. 3 A). Similar to what is observed in the chimeras 
(Fig. 1 B), huTLR8 gene expression level in the BM-trans-
planted animals correlated negatively with survival (Fig. S2 C). 
No difference was found in either the number or activation 
state of T cells in the BM of huTLR8Tg chimeras, compared 
with BM from WT mice, suggesting that disease in reconsti-
tuted mice did not result simply from the transfer of effector 
T cells (unpublished data). Organs of the reconstituted mice 
Figure 1. huTLR8 expression level strictly correlate with decrease survival in chimeric mice. (A) Mice were generated with a varying number of 
copies of huTLR8. Mice were from clone 6 (CL; n = 14), clone 23 (n = 8), clone 12 (n = 44), and clone 8 (n =18). (B) Data from spleens was collected from 
moribund animals and TaqMan was used to evaluate huTLR8 expression. huTLR8 expression was plotted against survival time. 26 spleens (n = 22 from 
clone 12; n = 4 from clone 23) are shown. (C) PBMCs from huTLR8Tg chimeras were assessed by flow cytometry for expression of H2b (C57BL/6; expressing 
the transgene) or H2d haplotypes (BALB WT). From 25 mice (n = 21 from clone 12; n = 3 from clone 23; n = 1 from clone 6). (D) Human TLR8 expression 
level in blood from huTLR8Tg chimeras (total number of mice 26; n = 21 from clone 12; n = 3 from clone 23; n = 2 from clone 6) and from TLR8TgCL8 
(n = 36) was evaluated by TAQMAN. Data are expressed as fold compared with huTLR8 expression level in clone 8 (E). 5 × 105 PBMCs from huTLR8Tg chimeras 
or C57BL/6 WT animals were stimulated with a specific RNA-based TLR8 agonist, ORN-8L, and 24 h later supernatants were harvested and assayed for 
TNF levels by ELISA; data are cumulative of n = 4 mice (mean ± SEM), 2 mice from TLR8TgCL12, 1 mice from TLR8TgCL6 and 1 mice from TLR8TgCL23. 
Data are from a representative experiment out of three independent experiments. (F and G) 5 × 105 PBMCs from human healthy donors (F; n = 3 donors; 
mean ± SEM), from TLR8TgCL12 chimeras, or from WT mice were stimulated with ORN-8L or LPS with or without bafilomycin A1 for 18 h. Stimulation 
with TLR4 ligand LPS was used as control (G; n = 4 mice; mean ± SEM).
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showing that activation occurs only in the myeloid cells 
carrying the huTLR8 transgene and does not result from 
the elevated levels of inflammatory cytokines in these mice 
(Fig. 4 C). Similarly DCs and monocytes in WT mice trans-
planted with huTLR8Tg chimeras bone marrow were highly 
activated (Fig. 4 D) and this activation resulted in the increased 
ability of huTLR8Tg DCs to activate OT-II CD4 cells as 
compared with WT DCs (Fig. 4 E).
huTLR8Tg chimeras had a significant decrease of naive 
CD4 and CD8 T cells (CD62Lhi CD44low), paralleled by an 
increase of cells that were CD44highCD62Llow, consistent with 
an effector/memory phenotype (Table 1). When stimulated 
with PMA/ionomycin in vitro, splenic CD4 and CD8 T cells 
number of lymphocytes both in circulation (Fig. 4 B) and in 
spleens (Fig. 4 A and Table 1).
We observed a slight increase in the percentage of cir-
culating and splenic neutrophils and monocytes (Table 1), which 
is likely due to the decrease in lymphocyte number. Indeed, 
no significant increase in their absolute number was seen in 
the mice (Fig. 4 B). In chimeras, transgenic C57BL/6 and 
nontransgenic BALB/c cells could be distinguished by MHC 
haplotype, permitting comparison of the activation state of 
nontransgenic and huTLR8-expressing transgenic myeloid 
cells in the same animals. Enhanced expression of co-stimulatory 
molecules was observed only on the huTLR8 transgenic 
C57BL/6-DCs and monocytes, in both spleen and blood, 
Figure 2. Multiorgan inflammation in huTLR8 chimera mice. (A) Organs from WT (II, IV, VI, VIII) or chimeric huTLR8Tg (I, III, V, VII) were stained with 
hematoxylin and eosin. Pancreas (I, II), kidney pelvis (III and IV), kidney (V and VI), and liver (VII and VIII). Arrows indicates normal glomerular structure in 
kidney sections from WT animals (VI) and evident glomerular abnormalities in kidney from huTLR8Tg animals (V). Sections of liver are represented in panel 
VII (huTLR8Tg) and panel VIII (WT). Additional pathology details in Fig. S2. Scale bar is 100 µm for all panels except V and VI which is 50 µm. (B) Cumulative 
data of the pathological score in the affected organs. n = 28 (n = 18 from clone 12; n = 4 from clone 23 and n = 6 from clone 6) and 14 for WT C57BL/6; 
(mean ± SEM). (C) Cytokines concentration in sera from TLR8TgCL12 (n = 15) and CTRL WT C57BL/6 mice (n = 18) was measured by Milliplex assay. 
(D) Pancreases from TLR8TgCL12 or CTRL WT C57BL/6 mice (total number of mice = 6/group) were harvested 40–60 d after birth, and the levels of pro-
inflammatory genes were evaluated by TaqMan. Data are expressed as fold increase compared with CTRL mice (mean ± SEM). (E) huTLR8Tg animals were 
sacrificed when moribund (age ranged from 44 to 140 d). The titers of double-stranded DNA specific antibody (anti-ds DNA) and ribonucleoprotein (anti-
RNP) specific antibody in the serum of TLR8TgCL12 chimeras (n = 27) and of age matched WT animals C57BL/6 (n = 37) were determined. *, P ≥ 0.05;  
**, P ≥ 0.01; ***, P ≥ 0.001.
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a clear preferential activation of the H2b+ C57BL/6 T cells 
(Fig. 5, C–E).
Human TLR8 signals independently of mouse TLR7
Previous findings have suggested cross-regulatory interactions 
between TLR7 and TLR8 in both expression and function 
(Wang et al., 2006; Demaria et al., 2010; Fukui et al., 2011). 
We found that the response to TLR8 ligands of TLR8TgCL8 
backcrossed onto TLR7-deficient mice was not diminished, 
demonstrating that human TLR8 signals independently of 
mouse TLR7 (Fig. 6 A). In addition we found that the level 
of expression of mouse TLR7 mRNA in spleens and purified 
cellular subsets of chimeras huTLR8Tg mice was significantly 
decreased (Fig. 6, B and C) which is consistent with previous 
findings that, TLR7 expression is substantially increased in the 
absence of mouse TLR8 (Demaria et al., 2010).
Human TLR8 activation in the joints promotes  
spontaneous and induced arthritis in mice
The TLR8TgCL12 chimeras, which have the longest lifespan 
of the high huTLR8-expressing chimeras (Fig. 1 A), sponta-
neously developed arthritis in both forelimbs and hindlimbs 
in animals that survived at least 90 d (Fig. 7, A and B). The 
joints of these animals show typical features of arthritis, in-
cluding synovial and periarticular inflammation, synovial 
hyperplasia, and cartilage damage (Fig. 7, A and B). This spon-
taneous arthritis is dependent on huTLR8; however, these 
animals usually die of pancreatitis soon after the onset of joint 
inflammation, limiting their utility for mechanistic studies. 
The stable transgenic mouse strain with relatively low ex-
pression of huTLR8, TLR8TgCL8, did not develop sponta-
neous arthritis, but did have enhanced susceptibility in the 
collagen-induced arthritis model (CIA; Fig. 8 A). The onset 
and the initial development of disease was comparable in 
TLR8TgCL8 and WT littermate controls; however, disease 
progression ceased at 4 wk in WT mice, typical of the mild 
disease seen in C57BL/6 mice. In contrast, disease progression 
continued in TLR8TgCL8 mice, leading ultimately to sig-
nificant exacerbation of both clinical (Fig. 8 A) and patho-
logical disease scores (Fig. 8, B–D). Whole ankle joints in 
TLR8TgCL8 mice showed increased synovial inflammation, 
pannus formation, cartilage destruction, and bone damage 
compared with WT controls (Fig. 8 E). In transgenic animals, 
the expression of huTLR8 in the joints correlated with the 
clinical score (unpublished data), as well as with the presence 
of macrophages (F4/80), and levels of proinflammatory cyto-
kines such as TNF, IL1-b, IL-6, and IP-10 and of the metal-
loproteinases MMP-9 and MMP-3 (Fig. 8 F and not depicted). 
These findings demonstrate that although huTLR8 is not re-
quired for the onset of arthritis in this mouse model, signaling 
through TLR8 leads to progression and exacerbation of the 
relatively mild, self-limiting disease that develops in C57BL/6 
mice strain.
from huTLR8Tg chimera produced significantly more IFN- 
and TNF than cells from WT animals (Fig. 5, A and B), sug-
gesting enrichment of Th1 cells.
T cells in huTLR8Tg mice do not express huTLR8, 
thus changes in T cell populations likely reflect interactions 
with huTLR8-expressing DCs. To address this hypothesis 
we looked in chimeras mice harboring T cells from both 
C57BL/6 and BALB/c haplotype and found that there was 
Figure 3. Pathology induced by huTLR8 expression is due to its 
activation in the hematopoietic compartment. (A) B6.SJLmice were 
transplanted with bone marrow from huTLR8Tg chimeras and monitored 
for survival. n = 45 for TLR8TgCL12>B6.SJL; n = 12 for TLR8TgCL6>B6.SJL; 
n = 12 for TLR8TgCL23>B6.SJL; and n = 12 for C57BL/6>B6.SJL. Data are 
cumulative of two independent experiments. (B) Organs from mice in A 
were harvested when mice were moribund. TLR8TgCL12>B6.SJL n = 19; 
n = 3 for TLR8TgCL6>B6.SJL; n = 3 for TLR8TgCL23>B6.SJL; and n = 9 for 
C57BL/6>B6.SJL (mean ± SEM). (C) Cellular subsets were isolated from 
spleens of B6.SJLmice transplanted with bone marrow from TLR8TgCL12 
chimeras. Gene expression of huTLR8 was evaluated by TaqMan. Cumulative 
data from three independent experiments; n = 5–10. Mean ± SEM.
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Figure 4. High expression level of huTLR8 leads to the intrinsic activation of DCs in mice. (A) Peripheral blood and spleens were harvested 
from high expressing huTLR8Tg chimeras (n = 14–17) or age-matched C57BL/6 (n = 17) mice, and cell numbers were assessed. (B) Absolute white cell 
numbers in blood of chimera mice from TLR8TgCL12 (n = 14) and WT C57BL/6 (n = 18). A and B show cumulative data of four independent experiments. 
(C) Spleens and peripheral blood cells from high expressing huTLR8Tg chimeras or WT controls were harvested, and co-stimulatory molecule expression 
was analyzed on CD11c+ cells in spleens (top) and blood (middle) and splenic CD11b+ cells (bottom). CD11c were gated based on the expression of 
MHC-class I. CD11b+ cells were gated on CD11cneg cells and on the expression of MHC class I. H2b (C57BL/6)-positive cells expressing huTLR8 (black 
line) were compared with H2b-negative cells (BALB/c, red line) not expressing huTLR8 in the same animal. Blue line, WT animal. CD11bpos CD11cneg 
monocytes in the spleen were gated on the expression of MHC-class I. H2b (C57BL/6)-positive cells expressing huTLR8 (black line) are compared with 
H2b-negative cells (BALB/c, red line) not expressing huTLR8. Plots are representative of at least three independent experiments. (D) Expression of 
co-stimulatory molecules in CD11c from spleens of TLR8TgCL12>B6.SJL (black line) or C57BL/6 (red line) chimeric mice. Plots are representative of at 
least three independent experiments. (E) CD11c cells were purified from spleens of TLR8TgCL12>B6.SJL (TLR8DC) or C57BL/6>B6.SJL (WTDC) chimeric 
mice. The CD11c+ cells were loaded with Ova323–339 and used to stimulate OT-II T cells at the indicated DC:T cells ratio. One representative experiment 
of two is shown. *, P ≥ 0.05; **, P ≥ 0.01.
JEM Vol. 210, No. 13 
Article
2909
the levels of IL-1b transcripts (Fig. 10 B) in these patients, 
which was not the case with mRNA for TLR7 or TLR9 
(Fig. 10 C). The correlation of both IL-1b production and 
disease activity with TLR8 expression is further supported by 
the normalization of TLR8 mRNA in SoJIA patients treated 
with the IL-1 receptor antagonist, Anakinra (Fig. 10 A, cohort 2). 
A similar increase was found in purified monocytes from 
SoJIA patients with active disease (Fig. 10 D) but not in neu-
trophils (not depicted), suggesting that difference in TLR8 
expression level in whole blood is not simply a reflection 
of altered peripheral blood populations. As patients with 
systemic arthritis have chronic overexpression of proinflam-
matory cytokines, we assessed the impact of IL-1b, IL-6, TNF, 
and IFN- on TLR8 expression. None of these cytokines 
had a significant effect on huTLR8 expression both in human 
PBMCs (Fig. 10 E) and in PBMCs from TLR8TgCL8 mice 
(Fig. 10F). Taken altogether, these data indicate that TLR8 
is overexpressed in patients with systemic arthritis and sug-
gest that the signaling through this receptor may play a role 
in the disease pathogenesis. This is particularly relevant in 
the context of our observations in the human TLR8 trans-
genic animals.
DISCUSSION
Considerable understanding has been developed in the past 
decade about the potential deleterious consequences for self-
nucleic acids recognition by TLR7 and 9 and selective antag-
onists of these two receptors are now being tested in clinical 
trials for the treatment of various autoimmune disorders 
(Barbalat et al., 2011; Guiducci et al., 2009). Despite some 
Altered expression of TLR8 in patients  
with systemic arthritis disease
TLR8 has a very distinct expression pattern as compare to 
TLR7 and TLR9 in human blood, it is expressed in mono-
cytes, mDCs, and neutrophils while TLR7 and TLR9 
are coexpressed, primarily on B cells and PDC (Fig. 9 A; 
Hattermann et al., 2007; Forsbach et al., 2008; Janke et al., 
2009). Gene expression profiling of stimulated human PBMCs 
reflected these differences in cellular distribution. PBMCs 
stimulated by a specific TLR8 ligand showed high levels of 
proinflammatory genes, including IL-6, IFN-, IL-1, IL-23 
and TNF, as well as chemokines involved in inflammatory 
responses. In contrast to TLR7 and TLR9, TLR8 ligand did 
not induce type 1 IFN-regulated gene, likely due to its lack 
of expression on PDC (Fig. 9 B). Thus TLR8-induced 
response is significantly different from the one induced by 
TLR7 (Fig. 9 C).
As we observed that TLR8 can exacerbate arthritis in 
the murine arthritis model (Fig. 8), we measured the level of 
expression of TLR8 in patients with arthritis and found an 
increased level both in patients with Systemic onset juvenile 
arthritis (SoJIA) and its adult equivalent, Still’s disease (Fig. 10 A). 
Patients affected by these diseases have a dysregulated produc-
tion of IL-1b and can be successfully treated with inhibitors 
of the IL-1 pathway. The triggering factors and the innate 
receptors responsible for this increase in IL-1b are, however, 
not yet defined (Mellins et al., 2011; Pascual et al., 2005). 
TLR8 mRNA expression was significantly higher in blood 
cells of both SoJIA and Still’s disease (Fig. 10 A). Furthermore, 
the expression of TLR8 mRNA correlated positively with 
Table 1. Frequencies of leukocytes in huTLR8Tg chimeras
Spleen Blood
WT huTLR8Tg WT huTLR8Tg
Total spleen cell number 6 × 107 ± 0.2 4 × 107 ± 0.8a
% % % %
CD3+CD4+ T cells 23 ± 0.7 19 ± 1.4 17 ± 1.2 9 ± 1.5b
  Naive (CD62Lhi CD44low) 72 ± 0.5 55 ± 4.6c 72 ± 3.5 53 ± 8.3a
  Effector (CD62Lhi CD44hi) 5.2 ± 0.4 6 ± 0.77 2 ± 0.5 3 ± 0.7
  Effector memory (CD62LlowCD44hi) 18 ± 0.7 35 ± 5.5c 18 ± 3.6 39 ± 8a
CD3+CD8+ T cells 12 ± 0.5 10 ± 0.7 9.3 ± 1.7 6 ± 1.1
  Naive (CD62Lhi CD44low) 74 ±1.1 58 ± 4.8 74 ± 2.7 46 ± 4b
  Effector (CD62Lhi CD44hi) 16 ± 0.7 15 ± 2.2 11 ± 1.6 23 ± 3.3b
  Effector memory (CD62LlowCD44hi) 7 ± 0.4 23 ± 6c 11 ± 3.3 24 ± 3.6a
T reg (CD4+ CD8+ FOXP3+) 1.5 ± 0.3 2 ± 0.4 2 ± 0.3 2 ± 0.4
CD19+ B cells 49 ± 1.7 47 ± 3.2 48 ± 4 38 ± 4a
Monocytes (CD11b+Ly6GF4/80+) 2 ± 0.2 3 ± 0.3 5 ± 0.6 11 ± 1.4b
Neutrophils (CD11b+Ly6G+F4/80) 1 ± 0.14 3 ± 0.4c 6 ± 1 20 ± 6c
CD11c+ DC 4 ± 0.3 3 ± 0.4 3 ± 0.5 4 ± 0.5
Data are from TLR8 Tg clone 12 sacrificed when moribund (50–120 d old) and matching C57BL/6 WT mice; n = 17/per group (mean ± SEM). Main cell populations are 
represented as percentage of total live spleen or blood cells. Subpopulations are in bold.
aP ≤ 0.05.
bP ≤ 0.01.
cP ≤ 0.001.
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cellular distribution and some different ligand specificity in vitro 
(Forsbach et al., 2008) and likely in vivo. We showed that 
activation of the TLR8 signaling pathway in human blood 
results in a predominant proinflammatory gene signature, 
whereas activation of TLR7 is associated with a type I IFN 
response, demonstrating that the cellular distribution of these 
two receptors is an essential element of their biology. In addi-
tion, understanding the role of TLR8 has proven difficult as 
the mouse TLR8 seems to differ from its human orthologue 
due to the lack of 5 aa that are key for RNA recognition.
Here, we generated mice expressing functionally active 
huTLR8 with a similar expression pattern to that in human 
significant species differences between rodents and human in 
TLR expression patterns, much of this knowledge has been 
gained from studies performed in mouse models of auto-
immune disease or gene-targeted mice (Christensen et al., 
2006; Deane et al., 2007; Barrat et al., 2007; Ewald et al., 2011; 
Mouchess et al., 2011; Walsh et al., 2012). TLR8 belongs to 
the same family as TLR7 and TLR9, but its role in disease has 
yet to be elucidated due to the lack of an appropriate animal 
model to study its function in vivo. Interpretation of the role 
of TLR8 in inflammation has relied mostly on work per-
formed on mouse TLR7, which shares with human TLR8 its 
ability to detect ssRNA in the endosome but has a different 
Figure 5. T cell compartment is highly activated in huTLR8Tg mice. (A and B) Splenocytes from either high expressing TLR8TgCL12 chimeras in 
which at least 95% of the hematopoietic compartment was H2bpos (C57BL/6) or C57BL/6 WT mice were stimulated in vitro for 2 h with PMA and ionomy-
cin. Percentages of CD4 and CD8 T cells producing TNF and IFN- were assessed by flow cytometry. (A) Representative dot plots. (B) Quantitation of data 
in A from one representative of three independent experiments (n = 3 mice; mean ± SEM). (C and D) TLR8TgCL12 chimeras were sacrificed and spleens 
were harvested. (C) CD3+CD4+ and (D) CD3+CD8+ T cells were gated based on the expression of MHC class I. (D) Right panel shows representative dot plot 
of CD3+CD4+ and CD3+CD8+ from C57BL/6 WT mice from three independent experiments. (E) Quantitative intramouse data showing naive, effector memory, 
and effector T cells population for both haplotypes (huTLR8Tg in red, WT in blue). **, P ≥ 0.01
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with syngeneic WT mice. It is interesting that the difference 
with syngeneic animals only occurs once disease is established 
(Fig. 7 C). A possible scenario is that the initial process of 
joint injury induces the release self-RNA–peptide complexes 
(Ganguly et al., 2009). Infiltrating or resident macrophages 
would respond to this self-RNA through huTLR8, but not 
mouse TLR8, leading to increased production of proinflam-
matory mediators, which further enhance the disease process 
in transgenic mice. This suggests that huTLR8 is not involved 
in the initial phase of disease, but becomes a key player in the 
maintenance phase. In patients with systemic arthritis, we 
found an increased level of TLR8 in PBMCs of SoJIA 
patients and in patients with Still’s disease. Such increase could 
be caused by differences in cellular composition, but we ob-
served a similar increase in purified monocytes from patients 
and a significant correlation with IL-1b. Interestingly, TLR8 
expression levels is not regulated by IL-1b or IL-6, thought to 
be a primary abnormality associated with systemic arthritis, in 
what could have been a positive feedback loop in these pa-
tients suggesting a different mechanism leading to TLR8 
increased expression. Our observations using the transgenic 
mice have highlighted the dramatic impact of a slight increase 
in TLR8 expression on the overall state of inflammation in vivo. 
The similar high expression level of TLR8 in patients with 
arthritis thus argues for a role of this receptor in the patho-
genesis of the disease.
We took advantage of the coexistence in the blood of the 
chimeras of WT H2d cells and H2b-TLR8-bearing cells and 
demonstrated a selective activation of huTLR8-expressing 
DCs and monocytes, indicating that huTLR8 signaling exerts 
a cell-intrinsic effect. A possible contributor to the DC and 
monocyte activation in huTLR8Tg chimeras are the elevated 
levels of anti-RNP Ab (Fig. 2 E), which can activate the 
receptor in virtue of their high affinity for ssRNA (Vollmer et al., 
2005). However, DCs and monocytes are similarly activated 
in BM-transplanted mice (Fig. 4, E and F) which have unde-
tectable levels of anti-RNP (data not shown), suggesting that 
these cells sense other type of RNA ligands or at least that 
anti-RNP IC are not exclusively responsible for their activa-
tion. In the majority of huTLR8Tg chimeras, huTLR8-DC 
activation is paralleled by a preferential activation of H2b 
T cells. Notably, in few of the very sick animals analyzed, we 
found over 80% of T cells with an effector memory pheno-
type, and in these cases both H2b cells and H2d T cells were 
activated to a similar extent (data not shown). Thus, a process 
initially confined to cognate activation of T cells by huTLR8-
DC can ultimately involve noncognate activation of T cells 
once the response reaches certain intensity. In the transgenic 
mice, activated DCs and monocytes infiltrating the pancreas, 
might be exposed to self-antigens in a highly stimulatory 
environment which can lead to T cell activation. It is there-
fore possible that the inflammatory process, initially geo-
graphically restricted to the pancreas or another organ, would 
results to a rapidly progressing disease in other organs in a 
T cell dependent manner. Construction of more sophisticated 
models to be able to simultaneously track TLR8 expression 
leukocytes. The severity of the specific phenotypes closely 
correlated with the expression levels of huTLR8 and rela-
tively small difference in its expression lead to inflammation 
in multiple organs.
Pancreas failure was likely the primary cause of death of 
huTLR8Tg chimeras. The histological features of the involved 
pancreas showed similarity with primary autoimmune pan-
creatitis in humans (AIP), including a dense leukocyte in-
filtration consisting of T cells, macrophages, and neutrophils 
associated with large areas of interstitial fibrosis (Zandieh and 
Byrne, 2007). Interestingly, huTLR8Tg mice develop extra-
pancreatic lesions in organs often affected in AIP patients, in-
cluding salivary glands inflammation, glomerulonephritis, and 
inflammation in the portal area of the liver (Finkelberg et al., 
2006; Zandieh and Byrne, 2007). Although it is difficult to 
accurately compare the levels of huTLR8 in these transgenic 
animals to the levels in human cells, our data clearly demon-
strate that the inflammatory status is directly proportional to 
level of huTLR8 expression. One may predict that in humans, 
increased level of huTLR8 expression or possibly improper 
intracellular compartmentalization might lead to loss of 
immune tolerance.
huTLR8Tg chimeras developed spontaneous joint in-
flammation and the stable line expressing lower huTLR8 lev-
els is more susceptible to collagen-induced arthritis as compared 
Figure 6. Human TLR8 can function in absence of mouse TLR7, 
but it regulates its expression levels. (A) 5 × 105 PBMCs from TLR7+/+ 
TLR8TgCL8 line and from TLR7/ TLR8TgCL8 were stimulated with a specific 
RNA-based TLR8 agonist, ORN-8L, supernatants were harvested at 24 h 
and assayed for cytokines levels by ELISA; One representative experiment 
of three is shown. n = 4; mean ± SEM. (B) Mouse TLR7 expression was 
evaluated by TaqMan in spleens of TLR8TgCL12 (n = 22) and TLR8TgCL23 
(n = 4) chimeras and WT C57BL/6 (n = 30; mean ± SEM). (C) Cellular subsets 
were isolated from spleens of TLR8TgCL12>B6.SJL mice or with C57BL/
6>B6.SJL, as described in the Materials and methods. Gene expression of 
mouse TLR7 was evaluated by TaqMan. (B and C) Cumulative data from 
three independent experiments; n = 5–10; mean ± SEM; ***, P ≥ 0.001.
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a form of TLR9 which no longer requires receptor proteo-
lysis for activation, sense extracellular self-DNA and die of a 
fulminating form of anemia (Mouchess et al., 2011). In ad-
dition, there is no obvious basis for chemical differences 
between mouse and human RNA and it is thus unlikely that 
the receptor is activated by a specific mouse RNA ligands 
not present in humans. However, we cannot exclude that 
sequence motifs preferentially recognized by huTLR8 might 
be more represented in mice than in humans. Another possi-
bility is that huTLR8 is activated by virus or microbe RNAs 
not present in humans. However, in mice transplanted with 
huTLR8Tg–bone marrow, the disease severity was greatly 
accelerated, a phenomena that likely resulted from the abun-
dance of self-RNA released as a consequence of the massive 
cell-death induced by the radiation, rendering the hypothesis 
of a specific mouse pathogens less plausible.
Previous work has shown that increased expression of 
TLR7 is sufficient, independently of any other genetic lesions, 
to break tolerance in mice (Deane et al., 2007; Walsh et al., 2012). 
Similarly, transgenic mice for the D34 mutation in the chap-
erone protein Unc93B1 preferentially transport TLR7 versus 
TLR9 in the signaling endosome and develop autoimmunity 
(Fukui et al., 2011). In both cases, mice developed a massive 
lymphoproliferation. Surprisingly, we did not observe myeloid 
cell expansion or any signs of lymphoproliferation in the 
huTLR8Tg mice. On the opposite, lymphopenia not lym-
phoproliferation characterized these animals, suggesting a 
profound difference between TLR8 versus TLR7.
Other disease traits significantly differentiate the conse-
quence of increased huTLR8 versus TLR7 signaling in mice. 
TLR7Tg mice develop glomerulonephritis, liver necrosis, 
and a severe form of anemia, whereas pancreas, joints, and sali-
vary glands are not affected, rendering the glomerulonephri-
tis aspect of the diseases as probably the only common trait 
between the two models. In the TLR7Tg mice, absence of 
B cells is sufficient to abrogate the entire spectrum of symptoms, 
including DC activation and expansion, demonstrating that 
excessive TLR7 signaling in B cells drives the disease in this 
model. In the huTLR8Tg mice, it is unlikely that B cells play 
a similar central role to the disease. In fact, B cells in these 
mice express very low huTLR8 and don’t expand or infiltrate 
the involved organs. The increased levels of nucleic acid–
specific antibodies in the huTLR8Tg mice, however, suggest 
a break of B cell tolerance in both DNA- and RNA-binding 
proteins, but this phenomena happened late in the disease 
pathogenesis in the chimeras and was absent in the BM-
transplanted animals. Mechanistically, it is more likely that 
DCs and macrophage activation plays the critical step in the 
initiation of the inflammatory process by producing proin-
flammatory cytokines such TNF, IL-1b, and IL-6, which can 
mediate end organ damage, and promoting Th1 priming and 
differentiation of CD8 T into IFN-/TNF-producing cells. 
Although the overexpression of either TLR7 or huTLR8 in 
mice leads to a strong inflammatory response and disease 
symptoms, the phenotype of the mice is thus drastically dif-
ferent. This is quite puzzling, as both receptors recognize 
and activation in the early phase of the disease are required to 
clarify this point.
Although it is well known that huTLR8 recognize and 
gets activated by ssRNA, a key question is to better understand 
which ligands activate the receptor in vivo to induce such a 
dramatic break of tolerance and where does this happen first. 
The receptor is not constitutively active as spontaneous pro-
duction of cytokines was not observed after in vitro culture 
of PBMCs from any of the transgenic lines. The sensing of 
extracellular RNA is also unlikely since in transgenic animals, 
huTLR8 required receptor proteolysis in the endosome for 
its activity. As shown recently for TLR9, the proteolytic 
processing in the endolysosomal compartment is an essential 
mechanism to avoid recognition of extracellular self-DNA 
(Ewald et al., 2011; Mouchess et al., 2011) and mice expressing 
Figure 7. Spontaneous arthritis develops in high expressing 
huTLR8Tg mice. (A) Chimera mice from TLR8TgCL12 (n = 6) and C57BL/6 
CTLR animals (n = 6) were euthanized 90 d after the birth, and paws and 
joints were fixed, sectioned, and stained with toluene blue. Representative 
sections of paws from WT mice (i) and TLR8TgCL12 mice (iii and v) and 
joints from WT (ii) and TLR8TgCL12 mice (iv and vi). (B) The histological 
changes, degree of inflammation, and cartilage damage were evaluated 
by a pathologist in a blinded fashion and scored 1–5 as followed: 1, mini-
mal; 2, mild; 3, moderate; 4, marked; 5, severe. Two paws and two ankles 
were evaluated for each animal and the scores were summed to obtain 
the histological disease score. ***, P ≥ 0.001. Bar, 300 mm.
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distribution of these receptors is the key differentiation 
element. In the huTLR8Tg mice, TLR8 is restricted to my-
eloid cells, whereas TLR7, in addition to myeloid cells, is also 
present in B cells, T cells, and PDCs. The cellular distribution 
of TLR8 in the transgenic mice is similar to the human, at 
ssRNA and one would predict a similar inflammatory response 
linked to increase expression. Some of the key differences 
were the targeted organs but also the cellular response. This 
could be caused by intrinsic differences in the biology of 
these receptors but it is tempting to postulate that the cellular 
Figure 8. huTLR8Tg mice have increased 
susceptibility to arthritis. (A) TLR8TgCL8 line 
and age-matched WT controls (left) were 
immunized with collagen and disease score 
was measured. Total arthritis score (left) and 
percentage of mice with clinical score equal 
or more than four (right) in the two strains is 
shown. One representative experiment (n = 10 
mice per group) of 4 is shown (40 mice total 
per group). Statistical significance was evalu-
ated with a two-way ANOVA test. (B– D) Rep-
resentative sections (hematoxylin and eosin 
stained) of normal (B), WT (C), and TLR8TgCL8 
(D) joints, sacrificed 80 d after CIA induction. 
(E) Cumulative data from histopathological 
evaluation in B–D. Animals were sacrificed at 
day 80 after CIA induction and joints of hind 
paws were fixed, sectioned, and stained with 
H&E. The four histological changes (inflam-
mation, pannus formation, cartilage, and bone 
damage) were evaluated by a pathologist in a 
blinded fashion as described in the Materials 
and methods. Table shows cumulative data 
from 2 independent experiments, TLR8TgCL8 
(n = 16) or WT (n = 15); mean ± SEM; a = P ≤ 
0.05 (F) Expression of F4/80 and TNF in the 
joints of TLR8TgCL8. The two front joints of 
each animal (WT or huTLR8Tg) were used to 
prepare RNA and F4/80, and TNF expression 
was evaluated by TaqMan. Animals were sac-
rificed 80 d after CIA induction. Number of 
joints 46 per group (mean ± SEM); data are 
cumulative of two independent experiments. 
P-values were calculated using a nonpara-
metric correlation test (Spearman). *, P ≥ 0.05; 
***, P ≥ 0.001. Bar, 100 µm.
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Figure 9. TLR8 signaling induces a discrete panel of proinflammatory genes in humans. (A) Cellular subsets were isolated from whole blood of 
healthy donors and expression of TLR7, 8, and 9 was analyzed by TaqMan assay. Relative Ct of the genes is shown in the table. Cumulative data from at 
least four independent donors is shown (mean relative CT ± SEM). (B and C) 4 × 105 PBMCs from four healthy donors were stimulated for 6 h with or 
without TLR7L (CL264; 5 µg/ml), TLR8L (ORN8L; 200 µg/ml), and TLR9L (C274; 0.3 µM). Stimulated samples from each donor were normalized to their own 
unstimulated control (in medium only). Transcripts over- and underexpressed at least twofold were selected. In B, representative genes are grouped by 
family; mean fold up-regulation is shown for each ligand. In C, Venn diagram depicts the overlap between TLR7, 8, and 9 ligands for all genes differentially 
expressed in the three conditions. (C) List of genes specifically up-regulated by TLR8 ligation (right), TLR7 ligation (left), and TLR9 ligation (middle). Notably, a 
class of TLR8-specific genes (highlighted in orange) belongs to a family coding for highly conserved RNA molecules component of RNP, which constitute 
potent TLR8 activators (Vollmer et al., 2005).
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in mTLR7 expression in cellular subsets expressing huTLR8. 
This could constitute a mechanism to prevent the simultaneous 
expression of both receptors behind a certain threshold level. 
The presence of TLR7 in myeloid cells in mice indeed suggests 
that it compensates for the lack of a functional TLR8 in mice, 
whereas in humans, both receptors are expressed in different 
least in the hematopoietic compartment, which makes the 
mice a relevant model to study TLR8 biology. Mouse TLR8 
does not deliver an activation signal but is critical to control 
mTLR7 expression and as such prevents the occurrence of 
TLR7-driven autoimmunity in mice (Demaria et al., 2010). 
In line with these findings, we observed a marked reduction 
Figure 10. The TLR8 pathway is dysregulated in systemic arthritis patients. (A) Expression of TLR8 in the blood of systemic-onset juvenile arthritis 
patients (SoJIA; two cohorts; left; n = 33) and Still’s disease patients (right; n = 31). The level of huTLR8 in each of the cohorts was normalized to the level 
of the gene in healthy volunteer cohorts (HV). Cohort 2 of the SoJIA patients was treated with Anakinra (IL-1 receptor antagonist), and levels of huTLR8 
gene expression was compared before and after treatment (red dots). (B) Expression levels of TLR8 were plotted against blood levels of IL-1b of SoJIA 
(cohort 1 and 2 combined) and Still’s disease. (C) Similarly to C levels of TLR7 and TLR9 are shown for SoJIA (cohort 1 and 2 combined). In B and C, 
p-values were calculated using a nonparametric correlation test (Spearman). (D) TLR8 expression levels in purified monocytes from SoJIA patients with 
active disease. Human PBMCs (E) or mouse PBMCs from huTLR8TgCL8 mice (F) were cultured for 16 h with 1 ng or 5 ng/ml (for human PBMCs) or 5 ng/ml 
(mouse PBMCs) of the indicated cytokines, and levels of huTLR8 expression were assessed by TaqMan. The experiments were conducted twice with a total 
of eight human donors (E) and nine mice (F). Shown is mean ± SEM. *, P ≥ 0.05; **, P ≥ 0.01; ***, P ≥ 0.001.
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of the liver, kidney, salivary gland, lung, brain, heart, and pancreas was con-
ducted by a pathologist during the course of the study. Multiple organs 
sections were evaluated for each organ. Inflammation was scored 1 to 4 as 
follow: 1, minimal; 2, mild; 3, moderate; 4, marked. Statistical significance 
among groups was calculated with a Mann-Whitney U test with p-values 
comparing chimeric mice to age-matched CTRL B6 animals. P-values were 
considered statistically significant at P ≤ 0.05. For evaluation of arthritic joints 
in the CIA model, both front and hind limbs from each animal were fixed, 
sectioned, and stained with H&E and toluidine blue, and the wrist and ankles 
were scored for pathological changes. The four histological changes (inflam-
mation, pannus formation, cartilage, and bone damage) were evaluated in a 
blinded fashion with the following criteria: Inflammation: 0, normal; 1, minimal 
infiltration of inflammatory cells in synovium and periarticular tissue of 
affected joints; 2, mild infiltration; 3, moderate infiltration with moderate 
edema; 4, marked infiltration affecting most areas with marked edema; 
5, severe diffuse infiltration with severe edema. Pannus: 0, normal; 1, minimal 
infiltration of pannus in cartilage and subchondral bone of marginal zone; 
2, mild infiltration of marginal zone with minor cortical and medullary bone 
destruction in affected joints; 3, moderate infiltration with moderate hard 
tissue destruction in affected joints; 4, marked infiltration with marked 
destruction of joint architecture, affecting most joints; 5, severe infiltration 
associated with total or near total destruction of joint architecture, affects all 
joints. Cartilage damage: 0, normal; 1, minimal to mild loss of toluidine blue 
staining with no obvious chondrocyte loss or collagen disruption in affected 
joints; 2, mild loss of toluidine blue staining with focal mild (superficial) 
chondrocyte loss and/or collagen disruption in affected joints; 3, moderate 
loss of toluidine blue staining with multifocal moderate (depth to middle 
zone) chondrocyte loss and/or collagen disruption in affected joints; 
4, marked loss of toluidine blue staining with multifocal marked (depth to deep 
zone) chondrocyte loss and/or collagen disruption in most joints; 5, severe 
diffuse loss of toluidine blue staining with multifocal severe (depth to tide 
mark) chondrocyte loss and/or collagen disruption in all joints. Bone resorp-
tion: 0, normal; 1, minimal, small areas of marginal zone/periosteal resorption, 
not readily apparent on low magnification; 2, mild, more numerous areas of 
marginal zone/periosteal resorption, readily apparent on low magnification, 
minor overall cortical and medullary bone loss; 3, moderate, obvious resorption 
of medullary trabecular and cortical bone without full thickness defects in 
entire cortex, loss of some medullary trabeculae, lesion apparent on low 
magnification; 4, marked, full thickness defects in cortical bone, often with 
distortion of profile of remaining cortical surface, marked loss of medullary 
bone; 5, severe, full thickness defects in cortical bone and destruction of joint 
architecture of all joints. For each animal, the four parameters were scored for 
each of the four joints analyzed and summed to obtain the individual score 
per parameter per mouse. Maximum score per parameter = 20/mouse. The 
disease sum score represents the summed scores of the individual parameters. 
Parameters for the various groups were then compared using a Mann-Whitney 
U test with significance set at P ≤ 0.05. For immunohistochemistry, frozen 
tissue sections were fixed in cold acetone before endogenous peroxidase 
quenching with H2O2. Immunohistochemistry was performed by means of 
the streptavidin-biotin-peroxidase complex method using the following primary 
antibodies: rat anti–mouse CD8, rat anti–mouse CD4, rat anti–mouse Gr-1, 
hamster anti–mouse CD11c (all from eBioscience), rat anti–mouse CD68 
(BioLegend). Binding of the primary antibody was revealed by specific 
secondary antibodies using the aminoethylcarbazole chromogenic substrate. 
Sections were counterstained with hematoxylin and evaluated under a 
DM2000 optical microscope (Leica).
In vitro stimulation of mouse blood. 5 × 105 PBMCs from huTLR8Tg 
chimeras or C57BL/6 WT animals were stimulated with a specific RNA-
based TLR8 agonist, ORN-8L (200 g/ml) and, 24 h later, supernatants 
were harvested and assayed for cytokine levels by ELISA.
In vitro assessment of TLR8 DC function. DCs were isolated using 
anti-CD11c magnetic beads (Miltenyi Biotec) from spleens of BM-transferred 
mice TLR8TgCL12>B6.SJL or C57BL/6>B6.SJL. Purity was assessed by 
flow cytometry and confirmed to be 80–90%. DC were loaded for 2 h 
cell types and induce a qualitatively different inflammatory 
response (Fig. 9).
In conclusion, using novel human TLR8 transgenic mice, 
we have identified TLR8 as a key player in autoimmune in-
flammation in human diseases and defined a link between 
TLR8 and arthritis both in mouse models but also in patients. 
Our data provide for the first time some clear understanding 
of the difference in the in vivo biology of TLR7 versus TLR8 
and argue for the importance of restricting excessive TLR7 or 
TLR8 response in vivo pointing to the existence of sophisti-
cated mechanisms controlling level of recognition of self-RNA 
in endosomes by these two receptors. We believe that we have 
uncovered the role of TLR8 in human autoimmune inflam-
matory diseases, which identifies TLR8 as a key potential target 
for clinical development
MATERIALS AND METHODS
Reagents. TLR8 agonist stabilized immunomodulatory RNA (ORN8-
liter; 5-M2UGCUGCUUGUG-/glycerol/-GUGUUCGUCGUM2-5) was 
previously described (Lan et al., 2007) and synthetized by Chemgenes Cor-
poration. Small molecule TLR7 agonists CL264 was from InvivoGen.
Transgenic mice and bone marrow chimeras. Transgenic mice expressing 
human TLR8 were generated using generated using BAC/ES technologies 
(Sparwasser and Eberl, 2007). A human BAC containing TLR8 was transfected 
into C57BL/6NTac ES cell line, and four clones were chosen with a range 
of inserted human TLR8 in the genome and used to generated transgenic 
mice expressing TLR8. The level of human TLR8 expression in whole blood 
or splenocytes of transgenic animals was assessed by real-time quantitative 
PCR analysis.
For bone marrow chimeras, C57BL/6SJL (CD45.1) female mice were 
irradiated with two doses of 450 rad at 3-h intervals from a cesium source 
and reconstituted 4 h later with 1.7 × 106 bone marrow cells from transgenic 
chimeras or WT C57BL/6 (CD45.2). Mice were kept on antibiotics (neomycin 
sulfate) for 3 wk. Flow cytometry analysis on blood was used to evaluate 
level of chimerism using anti-CD45.2 and anti-CD45.1 antibodies (BD). 
Animal experiments were conducted in Murigenics. All animal experiments 
were approved by the institutional animal care and use committee of Muri-
genics (IACUC), in conformity with the Guide for the Care and Use of 
Laboratory Animals (NRC).
Hematological and serological analysis. Mouse blood sample were ob-
tained from retro orbital bleeding and hematological parameters were assessed 
using the Heska CBC-Diff Veterinary Hematology System. Nucleic acids 
ds-DNA autoantibodies were evaluated with commercially available ELISA 
kits (Alpha Diagnostic). For anti-dsDNA assessment, sera were diluted 1:100 
or 1:30, respectively. For anti-RNP, sera were diluted 1:100 and assessed as 
previously described (Barrat et al., 2007).
Collagen-induced arthritis model (CIA). TLR8TgClone8 mice and 
WT (C57BL/6; littermate controls not expressing the transgene) were im-
munized per a published immunization schedule and protocol (Campbell 
et al., 2000). Animals were assessed for redness and swelling of the four limbs 
and the cumulative score of each mouse was the sum of the score obtained 
for each limb. The Clinical Score Guidelines were as follows: 0, normal; 
1, mild, but definite redness and swelling of the ankle or wrist, or apparent 
redness and swelling limited to individual digits, regardless of the number of 
affected digits; 2, moderate redness and swelling of ankle of wrist; 3, severe 
redness and swelling of the entire paw including digits; and 4, maximally 
inflamed limb with involvement of multiple joints.
Pathology. The biopsy specimens were fixed in formalin and embedded in 
paraffin and sections were stained with hematoxylin-eosin. Blinded evaluation 
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Isolation of mouse cellular subsets. Cellular subsets were purified from 
spleens of B6.SJL mice transplanted with bone marrow from TLR8TgCL12 
chimeras. Cellular subsets were routinely 90–95% pure. All reagents used 
were obtained from Miltenyi Biotec using the manufacturer’s instruction. 
Monocytes were obtained in a two-step process. First CD11c-positive cells 
were depleted using magnetic beads and monocytes were purified from the 
negative fraction using CD11b magnetic beads. DCs were positively selected 
using CD11c magnetic beads. CD8 T cells were purified by first depleting 
CD11c- and CD11b- positive cells followed by selection of CD8-positive 
cells using beads. Similarly, B cells were purified after depletion of both 
CD11c- and CD11b-positive cells followed by positive selection of B220-
positive cells. CD4+CD25 naive T cells and CD4+CD25+ T reg were puri-
fied using their respective kit. Neutrophils were purified from the bone 
marrow after depletion of CD11c+ cells and purification of LY6G-positive 
cells using magnetic beads. After purification, cells were immediately frozen 
in RLT buffer.
Isolation and in vitro stimulation of human cells and gene expres-
sion analysis. Whole Blood was obtained from healthy individual from Ad-
vanced Bioscience Resources. Buffy coats were obtained from the Stanford 
Blood Center (Palo Alto, CA). Cells were used under internal Institutional 
Review Board–approved protocols where all donors signed informed consent 
to allow the use of their blood for research purposes.
Cellular subsets were routinely 95–99% pure. mDC (BDCA1+ myeloid 
DCs), PDC (BDCA4+ plasmacytoid DCs) and naive B cells were positively 
selected using magnetic beads from Miltenyi Biotec. Regulatory T cells 
(CD4+CD25+) and CD4+CD25 naive CD4 T cells were isolated using a 
T reg purification kit from Miltenyi Biotec. Untouched monocytes (CD14+) 
were purified using a negative selection kit (Stem Cell). Untouched neutro-
phils were isolated using lympholyte-poly (Cedarlane Laboratories). RNA 
samples were extracted using the RNeasy Mini RNA Extraction kit (QIAGEN) 
according to manufacturer’s instructions. PBMCs were stimulated as de-
scribed in figure legend and RNA samples were extracted using the RNeasy 
Mini RNA Extraction kit (QIAGEN) according to manufacturer’s instruc-
tions. Patients’ blood samples for gene expression analysis were collected in 
Tempus tubes or ACT tube and immediately delivered to Baylor Institute for 
Immunology Research (Dallas, TX) at room temperature and stored 
at 20°C before processing.
Total RNA integrity was assessed using an Agilent 2100 Bioanalyzer 
showing a quality of RNA integrity number >7 (Agilent Technologies). 
RNA yield was assessed using a NanoDrop 1000 spectrophotometer 
(NanoDrop Products; Thermo Fisher Scientific). Biotinylated, amplified anti-
sense complementary RNA (cRNA) targets were then prepared from 250 ng 
of the total RNA using the Illumina TotalPrep RNA Amplification kit 
(Applied Biosystems). 750ng of the labeled cRNA was hybridized overnight 
to Illumina Human HT-12 V4 BeadChip arrays (Illumina), which contained 
more than 47,000 probes. The arrays were then washed, blocked, stained, and 
scanned on an Illumina iScan following the manufacturer’s protocols. Illumina 
GenomeStudio software v2011.1 with the Gene Expression v1.9.0 module 
(Illumina) was used to generate signal intensity values from the scans.
Statistical analysis. Data were analyzed using Mann Whitney Student’s 
t test, unless otherwise indicated in figure legends. All analyses were performed 
using Prism software v5 (GraphPad Software). Differences were considered 
significant at P < 0.05.
Online supplemental material. Fig. S1 shows details of the construct used 
to produce the huTLRTg mice. Fig. S2 shows the pathological assessment of 
organs inflammation in chimera mice expressing huTLR8 generated from 
ES clone 12, 6, and 23. Table S1 shows SoJIA Cohort 2 patients’ characteristic 
from Fig. 10 (A–C). Table S2 shows Still’s disease patients’ characteristic from 
Fig. 10 (A–C). Table S3 shows characteristic of the patients whose monocytes 
were used in experiment depicted in Fig. 10 D. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20131044/DC1.
with 2 g/ml Ova323–339 washed four time and cultured with 5 × 10*4 CD4 
T cells from OTII mice at the indicated concentration. Cultures were incu-
bated for 48 h and pulsed with [3H]thymidine for the last 8 h.
In vitro restimulation of T cells. Cells from spleen of TLR8TgClone 12 
chimeras mice and WT mice were stimulated in vitro for 2 h with PMA 
(5 ng/ml) and ionomycin (500 ng/ml) in the presence of 3µ/ml of brefeldin A. 
Subsequently, cells were stained for 15 min with T cells surface markers 
CD3, CD4, and CD8 wash and fixed and permeabilized with Cytofix/ 
Cytoperm (BD). Fluorochrome-conjugated monoclonal antibodies to TNF, 
IFN-, IL-4, and IL-10 were used to detect intracellular cytokines (BD). 
Flow cytometric analyses of PBMCs and splenocytes were performed using 
fluorochrome-conjugated monoclonal antibodies to mouse CD3, CD4, CD8, 
CD44, CD62L, CD80, GITRL, OX40L, CD40, CD19, CD23, CD21, LY6G, 
CD11b, CD11c, F480, and FOXP3 (BD). LSRII instrument (BD) was used to 
acquire flow cytometer data.
Cytokines detection. Antibody pairs for measuring mouse TNF and IL-12p40 
by ELISA were from RD system. TNF, IL-6, IL-17A, IL-12 p40, CCL-2 and 
IP-10 were determined in mouse serum by Milliplex assay (Millipore).
Real-time quantitative PCR (TaqMan) analysis. RNA was extracted 
from leukocytes using RNA micro kit (QIAGEN) and from pancreas tissues 
with fibrous tissue RNA extraction kit (QIAGEN) according to manu-
facturer’s instructions. RNA and cDNA was generated with SuperScript 
First-Strand Synthesis System (Invitrogen). TAQMAN reactions were per-
formed as described previously (Guiducci et al., 2010). Primer sequences 
have been previously described (Guiducci et al., 2010) and as follows: Human 
TLR7, forward 5-TTACCTGGATGGAAACCAGCTACT-3 reverse 
5-TCAAGGCTGAGAAGCTGTAAGCTA-3, human TLR9 forward 
5-TGAAGACTTCAGGCCCAACTG-3 reverse 5-TGCACGGTCAC-
CAGGTTGT-3. Human TLR8 primer (PPH01801B-200), mouse TLR7 
(PPM04208A-200), and mouse IFN- (PPM03121A-200) were obtained 
from SA Bioscience.
Patients and gene expression profiling. Pediatric patients and pediatric 
control were recruited at Baylor University Medical Center, Texas Scottish 
Rite Hospital, and Children’s Medical Center, all in Dallas, TX. The Study 
was approved by the institutional review board of all three institutions. Informed 
consents were obtained from all patients (legal representatives and patients 
over 10 yr of age).
Blood from SoJIA pediatric patients were as follows: patients in cohort 1 
(Fig. 10 A) were from day one untreated active patients in ANA-JIS clinical 
trial. This trial was registered at http://www.clinicaltrials.gov (registration 
number: NCT00339157) and details of patients are published in Quartier et al. 
(2011). 18 healthy age- and ethnicity-matched children were included and 
use to normalize the gene expression data of this cohort.
Blood samples from SoJIA pediatric patients in cohort 2 (Fig. 10 A) were 
from 12 patients who fulfilled the American College of Rheumatology 
diagnostic criteria (Cassidy et al., 1986). Patient blood was collected before 
starting treatment with Anakinra and after treatment (Table S1). Patients had 
active disease at day 1 before start of treatment and were considered in remission 
after Anakinra treatment. 15 healthy age- and ethnicity-matched children 
were included and use to normalize the gene expression data of this cohort.
Adult Systemic Onset Still’s disease patients were recruited at the Baylor 
Rheumatology clinic in Dallas (Berry et al., 2010). Patients had systemic 
symptoms and/or arthritis at the time of recruitment. Still’s disease patients’ 
characteristics are summarized in Table S2. Monocytes were purified from 
the blood of 15 SoJIA pediatric patients with active disease Monocytes from 
seven healthy age- and ethnicity-matched children were included and use to 
normalize the gene expression data (Table S3). PBMCs were isolated by density 
gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare). Monocytes 
were purified using either the EasySep Human Monocyte Enrichment kit 
(STEMCELL Technologies) followed by CD14+ selection using MACS kits 
(Miltenyi Biotec).
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